Insights Into Acute Lymphoblastic Leukemia (ALL)

Perspectives on current treatment practices regarding adult and AYA ALL, the role of MRD, and current treatment practices regarding relapsed disease

Elias Jabbour MD Anderson Cancer Center Aptitude Health

Meeting Chair

Elias Jabbour, MD

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Look Inside This Report

Download a sample of this report and start discovering the insights

Report Snapshot

Insights on the following therapies were obtained

  • pegaspargase
  • asparaginase
  • imatinib
  • dasatinib
  • ponatinib
  • blinatumomab
  • inotuzumab ozogamicin
  • chimeric antigen receptor (CAR) T-cell therapy

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • A moderated roundtable discussion focusing on treatment of ALL was held on October 26, 2019, in Seattle, WA
  • Disease state and data presentations were developed in conjunction with a medical expert from MD Anderson Cancer Center
  • The group of advisors comprised 8 community oncologists from the Northwest (USA)
  • Data collection was accomplished through use of audience response system questioning and in-depth moderated discussion

Explore Available and Upcoming Insight Reports

View Reports